前收市價 | 238.20 |
開市 | 239.30 |
買盤 | 0.00 x 0 |
賣出價 | 0.00 x 0 |
今日波幅 | 232.60 - 239.30 |
52 週波幅 | 232.60 - 379.70 |
成交量 | |
平均成交量 | 0 |
市值 | 無 |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | 無 |
業績公佈日 | 2024年8月01日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript May 2, 2024 Genmab A/S reports earnings inline with expectations. Reported EPS is $0.16 EPS, expectations were $0.16. Genmab A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to […]
Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.